Last reviewed · How we verify
Commercial Influenza vaccine
Commercial Influenza vaccine is a Biologic drug developed by Aramis Biotechnologies Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | Commercial Influenza vaccine |
|---|---|
| Sponsor | Aramis Biotechnologies Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine (PHASE1, PHASE2)
- H5N1 Milk Detection Study (NA)
- Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers. (PHASE2)
- Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects. (PHASE2)
- Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.' (PHASE3)
- Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated (PHASE4)
- Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine (PHASE4)
- To Explore a Bridging Index for the Effectiveness of the Clinical Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Commercial Influenza vaccine CI brief — competitive landscape report
- Commercial Influenza vaccine updates RSS · CI watch RSS
- Aramis Biotechnologies Inc. portfolio CI
Frequently asked questions about Commercial Influenza vaccine
What is Commercial Influenza vaccine?
Commercial Influenza vaccine is a Biologic drug developed by Aramis Biotechnologies Inc..
Who makes Commercial Influenza vaccine?
Commercial Influenza vaccine is developed by Aramis Biotechnologies Inc. (see full Aramis Biotechnologies Inc. pipeline at /company/aramis-biotechnologies-inc).
What development phase is Commercial Influenza vaccine in?
Commercial Influenza vaccine is in Phase 1.